Ipsen Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Ipsen is forecast to grow earnings and revenue by 7% and 5.5% per annum respectively. EPS is expected to grow by 6.9% per annum. Return on equity is forecast to be 14.8% in 3 years.

Wichtige Informationen

7.0%

Wachstumsrate der Gewinne

6.9%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	17.2%
Wachstumsrate der Einnahmen	5.5%
Zukünftige Eigenkapitalrendite	14.8%
Analystenabdeckung	Good
Zuletzt aktualisiert	31 Oct 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

We Think Shareholders May Consider Being More Generous With Ipsen S.A.'s (EPA:IPN) CEO Compensation Package

May 22

Ipsen (EPA:IPN) Has Affirmed Its Dividend Of €1.20

May 08

Ipsen (EPA:IPN) Has Affirmed Its Dividend Of €1.20

Apr 20

There's Reason For Concern Over Ipsen S.A.'s (EPA:IPN) Price

Apr 13

Ipsen (EPA:IPN) Seems To Use Debt Quite Sensibly

Mar 26

Investors Still Waiting For A Pull Back In Ipsen S.A. (EPA:IPN)

Dec 30

These 4 Measures Indicate That Ipsen (EPA:IPN) Is Using Debt Reasonably Well

Dec 11

Are Investors Undervaluing Ipsen S.A. (EPA:IPN) By 31%?

Sep 28

These 4 Measures Indicate That Ipsen (EPA:IPN) Is Using Debt Reasonably Well

Sep 07

Is There An Opportunity With Ipsen S.A.'s (EPA:IPN) 34% Undervaluation?

Jun 21

Ipsen (EPA:IPN) Is Due To Pay A Dividend Of €1.20

Jun 02

Ipsen's (EPA:IPN) Dividend Will Be €1.20

May 12

Ipsen S.A. (EPA:IPN) Shares Could Be 48% Below Their Intrinsic Value Estimate

Mar 19

Ipsen (EPA:IPN) Has A Pretty Healthy Balance Sheet

Mar 01

Ipsen (EPA:IPN) Ticks All The Boxes When It Comes To Earnings Growth

Jan 19

Is There An Opportunity With Ipsen S.A.'s (EPA:IPN) 46% Undervaluation?

Dec 08

We Think Ipsen (EPA:IPN) Can Manage Its Debt With Ease

Nov 02

Does Ipsen (EPA:IPN) Deserve A Spot On Your Watchlist?

Oct 14

Does Ipsen (EPA:IPN) Have A Healthy Balance Sheet?

Aug 01

Here's Why We Think Ipsen (EPA:IPN) Might Deserve Your Attention Today

Jul 10

Ipsen (EPA:IPN) Will Pay A Larger Dividend Than Last Year At €1.20

May 26

Gewinn- und Umsatzwachstumsprognosen

ENXTPA:IPN - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (EUR Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	3,927	800	848	1,109	11
12/31/2025	3,683	728	794	1,020	12
12/31/2024	3,487	625	630	849	13
6/30/2024	3,435	664	425	903	N/A
3/31/2024	3,371	641	554	884	N/A
12/31/2023	3,306	617	683	866	N/A
6/30/2023	3,282	406	764	972	N/A
3/31/2023	3,219	500	741	971	N/A
12/31/2022	3,156	593	719	971	N/A
9/30/2022	3,053	656	615	972	N/A
6/30/2022	2,950	719	512	973	N/A
3/31/2022	2,849	675	494	933	N/A
12/31/2021	2,749	631	475	893	N/A
9/30/2021	2,712	626	570	860	N/A
6/30/2021	2,676	622	665	827	N/A
3/31/2021	2,681	585	649	799	N/A
12/31/2020	2,686	548	632	771	N/A
9/30/2020	2,697	249	564	750	N/A
6/30/2020	2,707	-50	496	729	N/A
3/31/2020	2,700	-53	421	678	N/A
12/31/2019	2,693	-55	347	628	N/A
9/30/2019	2,605	176	310	591	N/A
6/30/2019	2,516	406	272	555	N/A
3/31/2019	2,432	397	279	563	N/A
12/31/2018	2,348	388	285	571	N/A
9/30/2018	2,258	365	N/A	N/A	N/A
6/30/2018	2,167	343	280	502	N/A
3/31/2018	2,090	307	N/A	463	N/A
12/31/2017	2,012	270	N/A	423	N/A
9/30/2017	1,923	243	N/A	N/A	N/A
6/30/2017	1,834	217	N/A	316	N/A
3/31/2017	1,753	221	N/A	317	N/A
12/31/2016	1,671	226	N/A	318	N/A
9/30/2016	1,623	229	N/A	N/A	N/A
6/30/2016	1,575	233	N/A	318	N/A
3/31/2016	1,548	211	N/A	271	N/A
12/31/2015	1,520	189	N/A	224	N/A
9/30/2015	1,468	165	N/A	225	N/A
6/30/2015	1,416	140	N/A	227	N/A
3/31/2015	1,374	147	N/A	237	N/A
12/31/2014	1,332	154	N/A	246	N/A
9/30/2014	1,310	155	N/A	217	N/A
6/30/2014	1,287	156	N/A	188	N/A
3/31/2014	1,284	149	N/A	188	N/A
12/31/2013	1,282	142	N/A	188	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: IPN's forecast earnings growth (7% per year) is above the savings rate (1.2%).

Ertrag vs. Markt: IPN's earnings (7% per year) are forecast to grow slower than the French market (12.3% per year).

Hohe Wachstumserträge: IPN's earnings are forecast to grow, but not significantly.

Einnahmen vs. Markt: IPN's revenue (5.5% per year) is forecast to grow slower than the French market (5.6% per year).

Hohe Wachstumseinnahmen: IPN's revenue (5.5% per year) is forecast to grow slower than 20% per year.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: IPN's Return on Equity is forecast to be low in 3 years time (14.8%).

Ipsen Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Ipsen S.A. Upgrades Earnings Guidance for the Full Year 2024

Ipsen S.A. Provides Earnings Guidance for the Full Year 2023

Ipsen S.A. Provides Earnings Guidance for the Financial Year 2023

Ipsen S.A. Upgrades Earnings Guidance for the Full Year 2022

Recent updates

Ipsen S.A. to Report Fiscal Year 2024 Results on Feb 13, 2025

What Ipsen S.A.'s (EPA:IPN) P/E Is Not Telling You

Ipsen Provides Update on CONTACT-02 Phase III Trial in Metastatic Castration-Resistant Prostate Cancer Following Final Overall Survival Analysis

These 4 Measures Indicate That Ipsen (EPA:IPN) Is Using Debt Reasonably Well

Ipsen Receives CHMPPositive Opinions for Iqirvo® (Elafibranor) in Primary Biliary Cholangitis and Kayfanda® (Odevixibat) in Alagille Syndrome, Two Rare Cholestatic Liver Diseases

First half 2024 earnings: EPS and revenues miss analyst expectations

Ipsen S.A. Upgrades Earnings Guidance for the Full Year 2024

An Intrinsic Calculation For Ipsen S.A. (EPA:IPN) Suggests It's 42% Undervalued

Genfit S.A. Announces the Successful Corporate Milestone with U.S. FDA Accelerated Approval of Ipsen's Iqirvo for Primary Biliary Cholangitis

Ipsen S.A. Approves Dividend, Payable on 3 June 2024

Ipsen (EPA:IPN) Has Announced A Dividend Of €1.20

Upcoming dividend of €1.20 per share

We Think Shareholders May Consider Being More Generous With Ipsen S.A.'s (EPA:IPN) CEO Compensation Package

Ipsen (EPA:IPN) Has Affirmed Its Dividend Of €1.20

Ipsen Announces Executive Changes

Ipsen (EPA:IPN) Has Affirmed Its Dividend Of €1.20

Dividend of €1.20 announced

There's Reason For Concern Over Ipsen S.A.'s (EPA:IPN) Price

Ipsen (EPA:IPN) Seems To Use Debt Quite Sensibly

Ipsen’s Onivyde Regimen, Potential New Standard-Of-Care First-Line Therapy in Metastatic Pancreatic Adenocarcinoma, Approved by FDA

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Ipsen Announces Latest Phase III Trial Data Investigating Cabometyx®? in Combination with Immunotherapy to Be Present at ASCO Gu 2024

Investors Still Waiting For A Pull Back In Ipsen S.A. (EPA:IPN)

These 4 Measures Indicate That Ipsen (EPA:IPN) Is Using Debt Reasonably Well

Ipsen Confirms U.S. FDA Grants Priority Review for New Drug Application for Elafibranor for the Treatment of Rare, Cholestatic Liver Disease, PBC

Ipsen and GENFIT Announces Full Results from the Pivotal Phase III ELATIVE Trial

Ipsen S.A. to Report Q4, 2023 Results on Feb 08, 2024

Ipsen S.A. to Report First Half, 2024 Results on Jul 24, 2024

Are Investors Undervaluing Ipsen S.A. (EPA:IPN) By 31%?

These 4 Measures Indicate That Ipsen (EPA:IPN) Is Using Debt Reasonably Well

IRLAB Therapeutics AB Announces Further Information on Results from Mesdopetam’s Clinical Phase IIb Study in Parkinson’s Disease Levodopa-Induced Dyskinesias and Phase III Preparatory Phase I Studies Performed by Ipsen

First half 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Profit margin trend

Ipsen Provides Update on E.U. Marketing Authorization Application for Bylvay for Cholestatic Pruritus in Patients with Alagille Syndrome

Ipsen Announces European Commission Decision on Palovarotene for the Treatment of FOP

Ipsen and GENFIT Announces Positive Results from Phase III ELATIVE Trial of Elafibranor in Patients with Primary Biliary Cholangitis, A Rare Cholestatic Liver Disease

Is There An Opportunity With Ipsen S.A.'s (EPA:IPN) 34% Undervaluation?

Ipsen Announces U.S. FDA Submission Acceptance of Its Supplemental New Drug Application for Onivyde Regimen in First-Line Metastatic Pancreatic Ductal Adenocarcinoma

Ipsen Announces U.S. FDA Approves Bylvay® for Patients Living with Cholestatic Pruritus Due to Alagille Syndrome

Ipsen to Present New Data

Ipsen (EPA:IPN) Is Due To Pay A Dividend Of €1.20

Ipsen S.A. Approves Dividend, Payable on 6 June 2023

Upcoming dividend of €1.20 per share at 1.1% yield

Ipsen's (EPA:IPN) Dividend Will Be €1.20

Ipsen S.A. Proposes Final Dividend for the Financial Year 2022, Payable on June 6, 2023

Full year 2022 earnings: EPS and revenues miss analyst expectations

Ipsen S.A. (EPA:IPN) Shares Could Be 48% Below Their Intrinsic Value Estimate

Ipsen (EPA:IPN) Has A Pretty Healthy Balance Sheet

Full year 2022 earnings: EPS and revenues miss analyst expectations

Ipsen S.A. Provides Earnings Guidance for the Full Year 2023

Ipsen Receives CHMP Negative Opinion for Palovarotene as a Treatment for Fibrodysplasia Ossificans Progressiva in E.U

Ipsen Presents Phase III NAPOLI 3 Trial of Onivyde(R) Regimen Demonstrating Positive Survival Results in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma At Asco GI

Ipsen (EPA:IPN) Ticks All The Boxes When It Comes To Earnings Growth

Ipsen S.A. (ENXTPA:IPN) entered into a definitive merger agreement to acquire Albireo Pharma, Inc. (NasdaqCM:ALBO) for approximately $870 million.

Ipsen S.A. Provides Update on Phase III CONTACT-01 Trial Evaluating Cabozantinib

Is There An Opportunity With Ipsen S.A.'s (EPA:IPN) 46% Undervaluation?

Ipsen Announces Onivyde® Regimen Demonstrated Statistically Significant Improvement in Overall Survival in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

We Think Ipsen (EPA:IPN) Can Manage Its Debt With Ease

Ipsen S.A. Provides Earnings Guidance for the Financial Year 2023

Ipsen S.A. to Report Fiscal Year 2022 Results on Feb 09, 2023

Ipsen S.A. to Report Q2, 2023 Results on Jul 27, 2023

Ipsen S.A. to Report Q3, 2022 Results on Oct 26, 2022

Does Ipsen (EPA:IPN) Deserve A Spot On Your Watchlist?

Ipsen Announces Results from Phase III RESILIENT Trial Evaluating Onivyde in Second-Line Monotherapy for Small Cell Lung Cancer

Does Ipsen (EPA:IPN) Have A Healthy Balance Sheet?

First half 2022 earnings released

Ipsen S.A. Upgrades Earnings Guidance for the Full Year 2022

Here's Why We Think Ipsen (EPA:IPN) Might Deserve Your Attention Today

Ipsen Announces U.S. FDA Priority Review for Palovarotene New Drug Application in Patients with Fibrodysplasia Ossificans Progressiva Following Resubmission

Ipsen Announces at ASCO 2022 New Cabometyx Data Show Encouraging Results in Monotherapy and in Combination Across Different Tumor Types

Ipsen (EPA:IPN) Will Pay A Larger Dividend Than Last Year At €1.20